Possible Efficacy and Safety of Mebendazole in Patients With Ulcerative Colitis Treated With Mesalamine

Launched by TANTA UNIVERSITY · Mar 27, 2024

Keywords

ClinConnect Summary

This clinical trial is looking into the potential benefits and safety of a medication called mebendazole for patients with ulcerative colitis, a type of inflammatory bowel disease. The study will focus on people who are already being treated with another medication called mesalamine. Researchers want to see if adding mebendazole can help improve their condition.

To be part of this trial, participants need to be at least 18 years old and have mild to moderate ulcerative colitis confirmed by a doctor using an endoscope (a tool that allows doctors to see inside the intestines). However, patients with severe ulcerative colitis or certain health issues, like liver or kidney problems, diabetes, or a history of cancer, won't qualify. The trial is not yet recruiting participants, so those interested will need to wait until it begins. If chosen, participants will receive guidance on what to expect during the study, including regular check-ups and monitoring for any side effects.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years old Both male and female will be included Mild and moderate UC patients diagnosed and confirmed by endoscope Patient treated with 5-aminosalislic acid (mesalamine)
• Exclusion Criteria:
• • - Patients with severe UC
• • Significant liver and kidney function abnormalities
• • Diabetic patients
• • Patients with Colorectal cancer patients
• • Patients taking rectal or systemic steroids
• • Patients on immunosuppressants or biological therapies
• • Addiction to alcohol and / or drugs
• • Known allergy to the studied medications
• • History of complete or partial colectomy.
• • Patients with congestive heart failure, other heart disease (arrhythmia, ischemic heart disease including angina and myocardial infarction).
• • Patients with other inflammatory diseases and active infection.
• • Patients with stressful condition (COPD, morbid obesity).
• • Patients with liver disease.
• • Patients with thrombocytopenia and neutropenia.
• • Patients with any type of seizures (case report for mebendazole induced convulsion).
• • Patients with renal disease (case report for mebendazole induced nephrotoxicity).
• • Patients with coagulation disorders.
• • Patients on metronidazole (to avoid Stevens-Johnson syndrome).
• • Patients with hypersensitivity to mebendazole, albendazole or benzimidazole
• • Patients using antioxidants.
• • Pregnant and lactating females.
• • Patients receiving, metronidazole, warfarin, low dose of aspirin, clopidogril, enzyme inducers (phenytoin, carbamazepine) and inhibitors (valoproate) to avoid potential pharmacodynamics and pharmacokinetic interactions.